Fentanyl Citrate

Drug Hikma Pharmaceuticals USA
Total Payments
$1.3M
Transactions
29
Doctors
7
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2024 $3,439 2 2
2023 $501.03 6 4
2022 $118,273 10 4
2021 $1.2M 11 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $1.3M 14 98.9%
Consulting Fee $12,863 3 1.0%
Food and Beverage $1,124 12 0.1%

Payments by Type

Research
$1.3M
14 transactions
General
$13,986
15 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Bedford NEMA Support Hikma Pharmaceuticals USA $1.3M 0

Top Doctors Receiving Payments for Fentanyl Citrate

Doctor Specialty Location Total Records
Unknown Bonita Springs, FL $1.3M 14
, MD Anesthesiology Evanston, IL $9,854 5
, MD Anesthesiology Boston, MA $3,556 4
, MD Anesthesiology Cleveland, OH $283.95 2
, D.O Anesthesiology Boston, MA $110.49 1
, MD Critical Care Medicine Evanston, IL $110.49 1
, C.R.N.P Pediatrics Philadelphia, PA $35.63 1
, M.D Anesthesiology Philadelphia, PA $35.62 1

About Fentanyl Citrate

Fentanyl Citrate is a drug associated with $1.3M in payments to 7 healthcare providers, recorded across 29 transactions in the CMS Open Payments database. The primary manufacturer is Hikma Pharmaceuticals USA.

Payment data is available from 2021 to 2024. In 2024, $3,439 was paid across 2 transactions to 2 doctors.

The most common payment nature for Fentanyl Citrate is "Unspecified" ($1.3M, 98.9% of total).

Fentanyl Citrate is associated with 1 research study, including "Bedford NEMA Support" ($1.3M).